APM
ANALYST COVERAGE2 analysts
BUY
Buy
2100%
2 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
PRICE
Prev Close
0.81
Open
0.84
Day Range0.82 – 0.85
0.82
0.85
52W Range0.65 – 4.47
0.65
4.47
5% of range
VOLUME & SIZE
Avg Volume
45.4K
FUNDAMENTALS
P/E Ratio
-4.4x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.48
Low vol
TECHNICAL
RSI (14)
49
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15

APM News

About

aptorum group limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. it also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. aptorum group limited was incorporated in 2010 and is headquartered in london, the united kingdom.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Country
United Kingdom
Kwok Kuen WongHead of Finance
Chung Yuen HuenFounder, Chief Executive Officer & Executive Director